Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.
Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses the COVID-19 pandemic's impact on clinical trial enrollment and the importance of open communication between patients participating in trials and their physicians.
Transcript
From your vantage point, is the pandemic still affecting clinical trial enrollment? What strategies have been effective for keeping trials going?
We definitely saw an impact on trial enrollment during COVID. Many of the clinicians told us about that. There's multiple reasons: Patients were afraid to come in, and the staff to do the work, they were either getting infected [or] they were not coming in. So, it definitely had an impact.
What we have seen is actually that enrollment has come back up, and I think that the NCI [National Cancer Institute] has actually reported on that as well—that, in general, clinical trial enrollment has come back up. Physicians and clinics have learned to deal with it, and I don't think that patients should be as concerned.
That being said, patients need to report if they get an infection to their physician on a clinical trial. As I said, there are steps that can be taken within the first 5 days. Patients should not hesitate to contact their physician if they're on a clinical trial and in the event that they get COVID.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More